CLBT logo

Cellebrite DI Ltd. (CLBT)

$11.94

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on CLBT

Market cap

$2.86B

EPS

-1.35

P/E ratio

--

Price to sales

7.85

Dividend yield

--

Beta

1.346069

Price on CLBT

Previous close

$13.16

Today's open

$13.05

Day's range

$11.76 - $13.06

52 week range

$11.76 - $20.86

Profile about CLBT

CEO

Tom Hogan

Employees

1167

Headquarters

Petah Tikva,

Exchange

Nasdaq Global Select

Shares outstanding

239470062

Issue type

Common Stock

CLBT industries and sectors

Technology

Software & IT Services

News on CLBT

Cellebrite Announces Participation in the Morgan Stanley Technology, Media & Telecom Conference

TYSONS CORNER, Va. and PETAH TIKVA, Israel, Feb. 24, 2026 /PRNewswire/ -- Cellebrite (NASDAQ: CLBT), a global leader in AI-powered Digital Investigative and Intelligence solutions for the public and private sectors,  today announced the Company will participate in the upcoming Morgan Stanley Technology, Media & Telecom Conference.

news source

PRNewsWire • 13 hours ago

news preview

Cellebrite DI Ltd. (CLBT) Q4 2025 Earnings Call Transcript

Cellebrite DI Ltd. (CLBT) Q4 2025 Earnings Call Transcript

news source

Seeking Alpha • Feb 12, 2026

news preview

Cellebrite Announces Record Fourth-Quarter and Full-Year 2025 Results

Total ARR grew 21% to $480.8 million; Revenue  grew 18% to $128.8 million Net income of $21.3 million supports non-GAAP net income of $36.7 million and adjusted EBITDA of $38.3 million, 29.8% adjusted EBITDA margin TYSONS CORNER, Va. and PETAH TIKVA, Israel, Feb. 11, 2026 /PRNewswire/ -- Cellebrite (NASDAQ: CLBT), a global leader in AI-powered Digital Investigative and Intelligence solutions for the public and private sectors, today announced financial results for the three and twelve months ending December 31, 2025.

news source

PRNewsWire • Feb 11, 2026

news preview

Cellebrite DI Ltd. (CLBT) Matches Q4 Earnings Estimates

Cellebrite DI Ltd. (CLBT) came out with quarterly earnings of $0.14 per share, in line with the Zacks Consensus Estimate.

news source

Zacks Investment Research • Feb 11, 2026

news preview

Cellebrite's 2026 Industry Trends Report Reveals Smartphones as the Leading Source of Digital Evidence in Investigations at 97%

97% cite smartphones as top evidence source, up 24 points from 2024 95% agree digital evidence increases solvability, yet 94% say complexity strains caseloads 65% believe AI can accelerate investigations, but one-third say policies prevent its use Cloud receptiveness hit 42%, yet two-thirds still rely on physical media TYSONS CORNER, Va. and PETAH TIKVA, Israel, Feb. 5, 2026 /PRNewswire/ -- Cellebrite (NASDAQ: CLBT), a global leader in AI-powered Digital Investigative and Intelligence solutions for the public and private sectors, today unveiled its 2026 Industry Trends Report, which surveyed 1,200 practitioners across 63 countries, marking the company's seventh annual report on how organizations collect, manage and analyze digital evidence.

news source

PRNewsWire • Feb 5, 2026

news preview

Artisan Small Cap Fund Q4 2025 Portfolio Activity

During the quarter, we initiated new positions in nLIGHT, Guardant Health and Cellebrite. We also added to Bruker, Hexcel and Penumbra during the quarter. Along with Insmed, we also ended our investment campaigns in Integer Holdings and SharkNinja during the quarter.

news source

Seeking Alpha • Jan 23, 2026

news preview

Cellebrite to Report Fourth-Quarter and Fiscal Year 2025 Financial Results on February 11, 2026

TYSONS CORNER, Va. and PETAH TIKVA, Israel, Jan. 21, 2026 /PRNewswire/ -- Cellebrite (NASDAQ: CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced it will report its fourth-quarter and fiscal year 2025 financial results before the U.S. markets open on Wednesday, February 11, 2026.

news source

PRNewsWire • Jan 21, 2026

news preview

Norwood Investment Partners Opens New $4.3 Million Cellebrite Position

Norwood initiated Cellebrite position and now holds 230,671 shares, worth an estimated $4.27 million. The stake represents 3.68% of 13F reportable assets under management.

news source

The Motley Fool • Dec 9, 2025

news preview

Cellebrite: Solid Setup Going Into Next Year

Cellebrite remains a "Buy" as federal demand rebounds and platform adoption accelerates, supporting a strong long-term growth outlook. The federal segment returned to year-over-year growth in Q3, removing the primary bear case and confirming demand was delayed, not lost. Inseyets migration and rapid cloud/SaaS ARR growth—Guardian cloud ARR up >100% for five quarters—position CLBT for outsized ARR acceleration into 2026.

news source

Seeking Alpha • Dec 5, 2025

news preview

10 AI Stocks Worth Buying Right Now

Artificial intelligence (AI) will reshape industries for decades, making early positioning in focused AI players critical. Smaller AI companies often offer more upside than megacaps that have already priced in the boom.

news source

The Motley Fool • Dec 4, 2025

news preview

¹ Disclosures

Get started with M1

Invest in Cellebrite DI Ltd.

Open an M1 investment account to buy and sell Cellebrite DI Ltd. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in CLBT on M1